---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-256300"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:47:37.574866+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement

## Summary
- Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.
- Cusack was Managing Director at Starboard Value LP (approx. $9B AUM) from 2011-2025.
- Appointment made pursuant to Cooperation Agreement with Rubric Capital Management LP dated Aug 8, 2025.
- Cusack will serve on the Nominating and Corporate Governance Committee.
- Director compensation follows standard non-employee director program described in April 2025 proxy.

## SEC filing metadata
- accession: 0001193125-25-256300
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/0001193125-25-256300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/hrtx-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-256300
- JSON: https://secwatch.observer/filing/0001193125-25-256300.json
- Plain text: https://secwatch.observer/filing/0001193125-25-256300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.